Loading
A phase 1/2 trial of ALLO-647, Fludarabine and Cyclophosphamide in chronic lymphocytic leukaemia, run by Allogene Therapeutics, active and no longer recruiting.
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) is a phase 1/2 interventional study registered as NCT04416984 by Allogene Therapeutics, with 160 participants enrolled, started 2020-05-21 and due to reach its primary completion in 2029-02. Interventions recorded: ALLO-501A, ALLO-647, Fludarabine and Cyclophosphamide.
Shares Allogene Therapeutics, Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.